Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. - Wikidata - wikimedia - TriplyDB

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.

http://www.wikidata.org/entity/Q34529488

about

Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3 Recent advances in understanding psoriasis Regulation of T Cell Immunity in Atopic Dermatitis by Microbes: The Yin and Yang of Cutaneous Inflammation Regulation of Dendritic Cell Function in Inflammation Jakpot! New small molecules in autoimmune and inflammatory diseases Nucleic acid delivery into skin for the treatment of skin disease: Proofs-of-concept, potential impact, and remaining challenges.Direct crosstalk between mast cell-TNF and TNFR1-expressing endothelia mediates local tissue inflammation.Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice.Emerging drugs for moderate-to-severe psoriasis.Expansion of parasite-specific CD4+ and CD8+ T cells expressing IL-10 superfamily cytokine members and their regulation in human lymphatic filariasis.Biologics in dermatologic therapy - an update.Possible association of IL-4 VNTR polymorphism with susceptibility to preeclampsia.The role of the T cell in autoimmune inflammation.Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin.New insights in the immunologic basis of psoriasis.GATA3 expression is decreased in psoriasis and during epidermal regeneration; induction by narrow-band UVB and IL-4 Allergic contact dermatitis in psoriasis patients: typical, delayed, and non-interacting.Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).Langerhans cells serve as immunoregulatory cells by activating NKT cells.Progress in understanding the immunopathogenesis of psoriasis Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.Identification and characterization of noncalcemic, tissue-selective, nonsecosteroidal vitamin D receptor modulators.IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis IL-23 induces atopic dermatitis-like inflammation instead of psoriasis-like inflammation in CCR2-deficient mice Platelet-activating factor is crucial in psoralen and ultraviolet A-induced immune suppression, inflammation, and apoptosis.Cytokine-based immunointervention in the treatment of autoimmune diseases.Genetic basis of psoriasis vulgaris and its pharmacogenetic potential.IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells Novel biological immunotherapies for psoriasis.Cytokine and anticytokine therapy in dermatology.Retinoic Acid promotes interleukin-4 plasmid-dimethylsulfoxide topical transdermal delivery for treatment of psoriasis.Signal transduction pathways and transcriptional regulation in Th17 cell differentiation Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells Evolution of biologic therapies for the treatment of psoriasis.Therapeutic potential of macrolide immunosuppressants in dermatology.Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus Psoriasis and the new biologic agents: interrupting a T-AP dance Use of Kv1.3 blockers for inflammatory skin conditions.Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor

P2860

Q24535580-565FBE22-840F-451E-ABEF-476D0A3D20F9 Q26751223-CE954C40-BDC8-445B-9F03-A194A17BDD49 Q26798464-22D97551-F6CB-4F13-9DD6-804AE87D93A1 Q26800988-0FBED862-2EF6-49DE-BEFE-EC7907CF5366 Q27001957-A9A58E60-95C7-4868-87C7-2BA69DFC81C5 Q28085200-368F1F2C-DE6A-420A-BA30-58A789977187 Q30489747-ACDFF061-F436-4661-B386-7998C2AFABA4 Q30931615-80AB25CA-BBC7-4FC5-8AF6-6E3E2147B7AD Q30984470-831AAAD3-9691-47C8-9985-8F4E8FDC67B9 Q31155684-15501AB8-7561-42BD-A32D-916203E40DD3 Q33607620-04A44AE9-086D-4C27-8C28-8A2EC6312269 Q33608821-2CB99E36-023F-4FF5-9293-D98C5CC9AFFF Q33709343-DA929E31-CFC0-4254-8A90-4179AD0A45A7 Q33830208-D870D817-3572-471F-A8AC-2D5ED6EF26E1 Q33844869-4DF97CFE-B9D5-46BC-9E9C-A2ECFF51CEB0 Q33911353-0BD4ADF2-3619-4FC6-81C1-85CE9730FB40 Q33945724-6E8C6D68-92B7-4DE2-97E6-6D994CB1AC23 Q34083054-943EA161-C038-4480-A1AD-B3C0A1DB0ABD Q34169114-5ECC954E-6993-4161-BCAA-87A811E61D93 Q34179869-7B3E0A93-B450-49DD-8368-3463B2B5E538 Q34215381-3F09C7CF-90D0-4ABF-BA7B-A4F76FC5CD21 Q34327203-267BF75A-9DD3-4ACF-A752-E5EBBF29CBD1 Q34435158-80A28319-582B-47ED-8C47-F41ADFAE3E5E Q34577866-1627254B-584C-47EE-A75C-7171DE709D7B Q34614791-7484BB87-7FFE-4E35-AEEC-7AE0931189F9 Q35053428-B0EEC058-F99D-4AAF-A49B-6D5E5F69DEE0 Q35109131-06ABD9D5-A80F-496A-8CE4-1135234BC64F Q35116099-F9F21CF3-48E0-43FC-AA8A-E04D4E8A7B7D Q35129052-FA326C88-2ABA-4701-9BF5-D23B725DD522 Q35164740-418775DD-FC2F-4B21-B8D4-4D4F68661536 Q35184711-CC027EB8-B06D-4B34-8125-A110386121EA Q35226768-C208C65A-93FA-4BAA-80E9-392DB508D128 Q35238480-0CBA7965-16F7-4EDB-A726-160BC486F5AA Q35441339-FBA21D4A-76B4-4486-80DB-D2C45C05AC1D Q35606903-EB129F9D-E747-4920-9145-500982EF5B30 Q35680649-6B4C9C6E-7A44-4834-A08B-3F7A34033E37 Q35741166-8EAE65E1-31EA-4E4C-998B-843818A63694 Q35813465-BD2B60E6-029D-461A-8C09-A7E827BF785F Q35915882-16508661-2F2C-4C35-B93D-F669C37DDA64 Q35945026-C0446516-C2F3-42AC-9654-32C5A5461848

P2860

Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease.

http://www.wikidata.org/entity/Q34529488

description

2002 nî lūn-bûn

@nan

2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@ast

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@en

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@nl

type

label

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@ast

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@en

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@nl

prefLabel

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@ast

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@en

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@nl

P1433

Q34529488-6F0D1C79-6EDF-4162-8CAD-30EC49986B4A

P1476

Q34529488-9467195D-926F-4446-AC39-B1D3FDD9C0C2

P2093

Q34529488-2649B442-ACC1-43FA-9FB7-D1BDA9BD58BB

Q34529488-331A9956-EDEF-429A-ACB4-057B2A98C985

Q34529488-38C56786-B047-43D1-8B29-17F0EF24BE48

Q34529488-3B3F5820-E0DC-46CA-B882-4C0BFED8AAFF

Q34529488-59495853-E767-4C68-BC93-156DD8303E22

Q34529488-6B60362B-FE2A-4FEF-80BB-7349705A961C

Q34529488-9E5C24CD-0A78-4B36-8018-F9C69A00650D

Q34529488-A4400DE7-1C29-4288-80E1-6901085BAF94

Q34529488-AA505769-D867-4019-8E71-14ABF49EF95C

Q34529488-B1E36EA5-FDDC-4E51-8CE8-F394C4E4B284

P2888

Q34529488-2CFF0FC2-EA11-4DCF-B0DE-C97DEB568282

P304

Q34529488-91B6ABCB-FD38-4AF8-B357-1C5E514A6293

P31

Q34529488-69984095-F244-4ADB-8147-C7887FE32E41

P356

Q34529488-7B93A25F-8D66-43F1-97C6-DCCA25F4CFD6

P407

Q34529488-3A28882E-CAE5-435D-AB27-514C0A4E7FB9

P433

Q34529488-F70A85DE-4470-4790-AE33-5C93AABFE134

P478

Q34529488-4842D14A-33B4-4795-843B-8A1173B4A49E

P50

Q34529488-CD77A19F-D25C-4E17-9951-B8D3F4DE8670

P577

Q34529488-A0788905-0A88-4481-960E-5E7B897ADD35

P5875

Q34529488-5E5AAA33-1955-41AD-B545-53D202116ACF

P698

Q34529488-A9A1850C-CA57-4458-A536-08DB7397D212

P921

Q34529488-27880b6a-111a-4541-8fae-59516db81d0d

P356

P1433

Nature Medicine

P1476

Interleukin-4 therapy of psori ...... oves human autoimmune disease.

@en

P2093

Christian A Sander

http://www.w3.org/2001/XMLSchema#string

Detlef Schlöndorff

http://www.w3.org/2001/XMLSchema#string

Enno Christophers

http://www.w3.org/2001/XMLSchema#string

Gerd Plewig

http://www.w3.org/2001/XMLSchema#string

Jörg Prinz

http://www.w3.org/2001/XMLSchema#string

Kamran Ghoreschi

http://www.w3.org/2001/XMLSchema#string

Martin Dugas

http://www.w3.org/2001/XMLSchema#string

Martin Röcken

http://www.w3.org/2001/XMLSchema#string

Matthias Mack

http://www.w3.org/2001/XMLSchema#string

Peter Thomas

http://www.w3.org/2001/XMLSchema#string

P2888

P304

40-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM804

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Willem van Eden

P577

2002-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11008478

http://www.w3.org/2001/XMLSchema#string

P698

12461524

http://www.w3.org/2001/XMLSchema#string

P921